NTR
Jessica Alvarez, Atlanta, USA
Division of Endocrinology, Metabolism & Lipids
Emory University School of Medicine
Shari Willy, MPH, RD, LDE, CACFD (she/her/hers)
University of Louisville
The addition of highly effective modulator therapies (HEMTs), namely elexacaftor/ivacaftor/tezacaftor (ETI), has presented nutrition challenges in people with cystic fibrosis (PwCF). This workshop will examine current research on HEMTs and how they relate to nutrition status in PwCF. Changes in the gastrointestinal microbiome, inflammation, absorption, and growth parameters as a result of ETI use will be discussed.
Speaker: Nicole Green, MD (she/her/hers) – Pediatric Gastroenterology, Seattle Children's Hospital, Seattle, WA, USA
Speaker: Julie L. Sanville, DO, FAAP (she/her/hers) – Dartmouth-Hitchcock Medical Center
Speaker: Amber L. James, MPH (she/her/hers) – University of Virginia
Speaker: Kasey Wilburn, RD (she/her/hers) – University of Virginia
Speaker: Jennifer T. Duong, MD (she/her/hers) – UCSF Benioff Children's Hospital